Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Price Target from Analysts

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) has earned a consensus recommendation of "Buy" from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $24.13.

Several equities research analysts have recently commented on RZLT shares. HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of Rezolute in a research note on Friday, November 8th. Guggenheim assumed coverage on shares of Rezolute in a report on Tuesday, August 27th. They set a "buy" rating and a $11.00 target price for the company. JMP Securities reiterated a "market outperform" rating and issued a $7.00 target price on shares of Rezolute in a report on Friday, September 20th. Wedbush reaffirmed an "outperform" rating and issued a $112.00 price target on shares of Rezolute in a research note on Monday, November 4th. Finally, Maxim Group raised their price objective on shares of Rezolute from $8.00 to $10.00 and gave the stock a "buy" rating in a report on Tuesday, August 6th.

Rezolute Trading Down 1.4 %

RZLT traded down $0.07 during midday trading on Tuesday, reaching $4.79. The company's stock had a trading volume of 186,048 shares, compared to its average volume of 427,618. The stock has a market cap of $277.53 million, a P/E ratio of -3.77 and a beta of 1.18. Rezolute has a twelve month low of $0.72 and a twelve month high of $6.19. The company has a fifty day simple moving average of $5.12 and a 200 day simple moving average of $4.61.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.14). Sell-side analysts expect that Rezolute will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Jeppson Wealth Management LLC acquired a new stake in shares of Rezolute during the 2nd quarter worth about $45,000. MML Investors Services LLC bought a new position in Rezolute in the third quarter valued at about $57,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Rezolute in the 3rd quarter valued at approximately $65,000. Virtu Financial LLC bought a new stake in Rezolute during the 1st quarter worth $37,000. Finally, XTX Topco Ltd grew its holdings in shares of Rezolute by 205.8% during the second quarter. XTX Topco Ltd now owns 33,671 shares of the company's stock worth $145,000 after purchasing an additional 22,660 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.